Expert Interview
Discussing the potential use of schizophrenia prescription digital therapeutics (PDT) with a close look at the CT-155 software from Boehringer Ingelheim and Click Therapeutics.
Ticker(s): BOEHRINGER INGELHEIM, Click TherapeuticsInstitution: University of Indiana
- Professor of Psychiatry at the University of Indiana
- Manages approximately 50 schizophrenia patients each month.
- Research focus on schizophrenia; author on Emergent trial published in NEJM.
Roughly how many patients do you manage with schizophrenia?
Added By: ben_adminWhat do you think about the potential of schizophrenia prescription digital therapeutics? Where would they fit into your treatment algorithm?
Added By: ben_adminWhat future data on CT-155 would be impactful to you?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
